Skinny Shot “Tirzepatide” works in several ways: it only increases insulin production when your blood sugar rises, minimizing the risk of low blood sugar. It decreases food intake and slows down gastric emptying, or how fast food travels through your digestive tract. This helps you feel fuller for longer and reduces the amount of food consumed.

Skinny Shot “Tirzepatide” helps you lose weight by lowering your blood sugar levels right away, although it may take 8-12 weeks to reach your target AIC goal. Your doctor will gradually increase your dose of Skinny Shot Club™ until the optimal amount is found for you, which could take several weeks or months before seeing the full impact on your blood sugar levels.

With the placebo, the average weight loss was 3.7%. With 5mg of Skinny Shot “Tirzepatide”, the average weight loss was 15%. With 10mg of Skinny Shot “Tirzepatide”, weight loss increased to 19% – meaning a 200-lb client may expect to lose nearly 40 lbs. Initial results are typically noticeable within 1-2 weeks.

Skinny Shot “Tirzepatide” is a first-in-class medicine that activates both the GLP-1 and GIP receptors, leading to improved blood sugar control. It is administered subcutaneously (under the skin) once per week, which is a pain free method of administration.

Skinny Shot “Tirzepatide” acts on both the GIP and GLP-1 receptors, while Ozempic® acts solely on the GLP-1 receptor.

Skinny Shot “Tirzepatide” helps manage blood sugar levels by increasing insulin production and reducing the amount of sugar your liver produces. Over time, high blood sugar can lead to serious health problems, including heart disease, vision loss, and kidney disease.

The most common side effects of Skinny Shot “Tirzepatide” include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach (abdominal) pain. These are not all the possible side effects of Skinny Shot “Tirzepatide”. Talk to your healthcare provider about any side effects that bother you or do not go away.

Client receiving Skinny Shot “Tirzepatide” in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (See adverse reactions, drug interactions). It is not known if Skinny Shot “Tirzepatide” can be used in people who have had inflammation of the pancreas (pancreatitis). Skinny Shot “Tirzepatide” is not for use in people with type 1 diabetes. It is not known if Skinny Shot “Tirzepatide” is safe and effective for use in children under 18 years of age.